Gemina Laboratories Ltd.
OTC: GLABF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Crandall Greene
- Employees
- 6
- Headquarters
- Burnaby, Canada
- IPO year
- 2022
- Market cap
- $3.8M
- Website
- https://www.geminalabs.com
Loading GLABF…
Loading profile data…Frequently asked questions about GLABF
What does Gemina Laboratories Ltd. (GLABF) do?
Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends to developing unique surface functionalization chemistries specifically designed for the identification of pathogens and various biological markers...
Where does GLABF trade?
Gemina Laboratories Ltd. (GLABF) trades on the Other OTC.
What sector is GLABF in?
Gemina Laboratories Ltd. (GLABF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gemina Laboratories Ltd.?
Robert Crandall Greene is the chief executive officer of Gemina Laboratories Ltd. (GLABF).
Where is Gemina Laboratories Ltd. headquartered?
Gemina Laboratories Ltd. is headquartered in Canada.
Does GLABF pay a dividend?
Gemina Laboratories Ltd. (GLABF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLABF go public?
Gemina Laboratories Ltd. (GLABF) completed its initial public offering in 2022.